Interleukin-6 has been postulated as a key mediator for inflammatory macular oedema, and tocilizumab appears to be of particular benefit in individuals with uveitic macular oedema.68, –70 The janus-associated kinase pathways mediate cell responses to several inflammatory cytokines involved in uveitis including IL-2 and IL-6, and JAK inhibitors such as baricitinib and tofacitinib have been shown to control disease in individuals whose uveitis has failed to respond to other immunomodulators.71 The gene discussed is IL2; the disease is uveitis.